Valuing SF-6Dv2 in Australia Using an International Protocol.

Mulhern, B; Norman, R; Brazier, J

Valuing SF-6Dv2 in Australia Using an International Protocol.

Mulhern, B

Norman, R Brazier, J

Permalink

Publisher:: ADIS INT LTD
Publication Type:: Journal Article
Citation:: PharmacoEconomics, 2021
Issue Date:: 2021-07-12

Closed Access

	Filename	Description	Size
	Valuing SF-6D2 in Australia Using an International Protocol.pdf	Published version	810.65 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Mulhern, B https://orcid.org/0000-0003-3656-8063
dc.contributor.author	Norman, R
dc.contributor.author	Brazier, J
dc.date.accessioned	2021-08-30T03:12:37Z
dc.date.available	2021-05-18
dc.date.available	2021-08-30T03:12:37Z
dc.date.issued	2021-07-12
dc.identifier.citation	PharmacoEconomics, 2021
dc.identifier.issn	1170-7690
dc.identifier.issn	1179-2027
dc.identifier.uri	http://hdl.handle.net/10453/150266
dc.description.abstract	<h4>Background</h4>The SF-6Dv2 is an updated version of the SF-6D, with improved consistency and dimension descriptors, and value sets are required. The aim of this study was to estimate an SF-6Dv2 value set for Australia using an international protocol, while secondary aims were to compare Australian and UK values and to understand heterogeneity.<h4>Methods</h4>The study design was based on the SF-6Dv2 valuation protocol, which involved the administration of two different discrete choice experiment (DCE) tasks. The first task presented pairs of SF-6Dv2 health states with duration (Design 1), and the second task presented triplets that appended 'immediate death' to the health state pairs (Design 2). Respondents completed 12 choice sets online (10 from Design 1; 2 from Design 2). Value sets were estimated for Design 1 separately and combining Designs 1 and 2 using a variety of logit model specifications. Value set characteristics were compared descriptively with the UK model.<h4>Results</h4>The sample included 3001 Australians. A range of ordered and consistent models were estimated. The models only including Design 1 data resulted in a relatively wider utility range. The value range was reduced by an interaction added when the health state included a dimension with a severe level. The model matched with the UK value set resulted in a larger utility range and consistent ordering of the most important dimensions.<h4>Conclusion</h4>The model including the Design 1 data and moderating interaction was chosen for the Australian value set. This allows the SF-6Dv2 to be used in health technology assessment decision making in Australia.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	ADIS INT LTD
dc.relation.ispartof	PharmacoEconomics
dc.relation.isbasedon	10.1007/s40273-021-01043-4
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	11 Medical and Health Sciences, 14 Economics
dc.subject.classification	Health Policy & Services
dc.title	Valuing SF-6Dv2 in Australia Using an International Protocol.
dc.type	Journal Article
utslib.location.activity	New Zealand
utslib.for	11 Medical and Health Sciences
utslib.for	14 Economics
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Business
pubs.organisational-group	/University of Technology Sydney/Strength - CHERE - Centre for Health Economics Research and Evaluation
utslib.copyright.status	closed_access	*
dc.date.updated	2021-08-30T03:12:36Z
pubs.publication-status	Published

Abstract:

Background

The SF-6Dv2 is an updated version of the SF-6D, with improved consistency and dimension descriptors, and value sets are required. The aim of this study was to estimate an SF-6Dv2 value set for Australia using an international protocol, while secondary aims were to compare Australian and UK values and to understand heterogeneity.

Methods

The study design was based on the SF-6Dv2 valuation protocol, which involved the administration of two different discrete choice experiment (DCE) tasks. The first task presented pairs of SF-6Dv2 health states with duration (Design 1), and the second task presented triplets that appended 'immediate death' to the health state pairs (Design 2). Respondents completed 12 choice sets online (10 from Design 1; 2 from Design 2). Value sets were estimated for Design 1 separately and combining Designs 1 and 2 using a variety of logit model specifications. Value set characteristics were compared descriptively with the UK model.

Results

The sample included 3001 Australians. A range of ordered and consistent models were estimated. The models only including Design 1 data resulted in a relatively wider utility range. The value range was reduced by an interaction added when the health state included a dimension with a severe level. The model matched with the UK value set resulted in a larger utility range and consistent ordering of the most important dimensions.

Conclusion

The model including the Design 1 data and moderating interaction was chosen for the Australian value set. This allows the SF-6Dv2 to be used in health technology assessment decision making in Australia.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/150266